NMN in Adversity, Where Are The Opportunities For Enterprises?

After the foam, NMN ushered in a new round of upsurge in 2022.

At the beginning of 2022, the information of the SFDA successively passed the NMN of 3 enterprises（ β- Nicotinamide mononucleotide) was put on record as a cosmetic raw material, which brought a glimmer of hope to the previously cold NMN industry, and many enterprises became active.

According to the data of iiMedia, the market scale of China's NMN component health products reached RMB 5.106 billion in 2020, with a year-on-year increase of 34.87%. It is expected that it will rise to RMB 27.013 billion at a growth rate of nearly 70.25% by 2023.

The growth rate of the NMN market is amazing. However, NMN, which has experienced the foam for a long time, will still face very clear challenges and risks even if it sets sail again. The lack of efficacy verification, laws, and regulations, as well as the always accompanying exaggerated and even false publicity, have made NMN deeply in the dilemma of "it is difficult to live up to its reputation". What should we do?